Literature DB >> 29781575

BRN2, a POUerful driver of melanoma phenotype switching and metastasis.

Mitchell E Fane1,2, Yash Chhabra1,2, Aaron G Smith1, Richard A Sturm2.   

Abstract

The POU domain family of transcription factors play a central role in embryogenesis and are highly expressed in neural crest cells and the developing brain. BRN2 is a class III POU domain protein that is a key mediator of neuroendocrine and melanocytic development and differentiation. While BRN2 is a central regulator in numerous developmental programs, it has also emerged as a major player in the biology of tumourigenesis. In melanoma, BRN2 has been implicated as one of the master regulators of the acquisition of invasive behaviour within the phenotype switching model of progression. As a mediator of melanoma cell phenotype switching, it coordinates the transition to a dedifferentiated, slow cycling and highly motile cell type. Its inverse expression relationship with MITF is believed to mediate tumour progression and metastasis within this model. Recent evidence has now outlined a potential epigenetic switching mechanism in melanoma cells driven by BRN2 expression that induces melanoma cell invasion. We summarize the role of BRN2 in tumour cell dissemination and metastasis in melanoma, while also examining it as a potential metastatic regulator in other tumour models.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CDKN2A; POU; epigenetic; phenotype switching; transcription factor

Mesh:

Substances:

Year:  2018        PMID: 29781575     DOI: 10.1111/pcmr.12710

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  19 in total

Review 1.  BRAF in malignant melanoma progression and metastasis: potentials and challenges.

Authors:  Aljawharah Alqathama
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

2.  Establishment of resveratrol and its derivatives as neuroprotectant against monocrotophos-induced alteration in NIPBL and POU4F1 protein through molecular docking studies.

Authors:  Ruchi Yadav; Prachi Srivastava
Journal:  Environ Sci Pollut Res Int       Date:  2019-11-30       Impact factor: 4.223

3.  Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.

Authors:  Jana Travnickova; Sonia Wojciechowska; Ava Khamseh; Philippe Gautier; Daniel V Brown; Thomas Lefevre; Alessandro Brombin; Ailith Ewing; Amy Capper; Michaela Spitzer; Ramile Dilshat; Colin A Semple; Marie E Mathers; James A Lister; Eiríkur Steingrimsson; Thierry Voet; Chris P Ponting; E Elizabeth Patton
Journal:  Cancer Res       Date:  2019-10-03       Impact factor: 12.701

Review 4.  Rethinking the biology of metastatic melanoma: a holistic approach.

Authors:  Hendrik Hld Vandyck; Lisa M Hillen; Francesca M Bosisio; Joost van den Oord; Axel Zur Hausen; Véronique Winnepenninckx
Journal:  Cancer Metastasis Rev       Date:  2021-04-19       Impact factor: 9.264

5.  Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.

Authors:  Nathaniel R Campbell; Anjali Rao; Miranda V Hunter; Magdalena K Sznurkowska; Luzia Briker; Maomao Zhang; Maayan Baron; Silja Heilmann; Maxime Deforet; Colin Kenny; Lorenza P Ferretti; Ting-Hsiang Huang; Sarah Perlee; Manik Garg; Jérémie Nsengimana; Massimo Saini; Emily Montal; Mohita Tagore; Julia Newton-Bishop; Mark R Middleton; Pippa Corrie; David J Adams; Roy Rabbie; Nicola Aceto; Mitchell P Levesque; Robert A Cornell; Itai Yanai; Joao B Xavier; Richard M White
Journal:  Dev Cell       Date:  2021-09-15       Impact factor: 12.270

6.  STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.

Authors:  Biniam Adane; Gabriela Alexe; Bo Kyung A Seong; Diana Lu; Elizabeth E Hwang; Denes Hnisz; Caleb A Lareau; Linda Ross; Shan Lin; Filemon S Dela Cruz; Melissa Richardson; Abraham S Weintraub; Sarah Wang; Amanda Balboni Iniguez; Neekesh V Dharia; Amy Saur Conway; Amanda L Robichaud; Benjamin Tanenbaum; John M Krill-Burger; Francisca Vazquez; Monica Schenone; Jason N Berman; Andrew L Kung; Steven A Carr; Martin J Aryee; Richard A Young; Brian D Crompton; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2021-06-14       Impact factor: 38.585

7.  BRN 2 Invade.

Authors:  Gaurav Pathria; Ze'ev A Ronai
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

8.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

Review 9.  Cell Adhesion Molecules in Plasticity and Metastasis.

Authors:  Jessica A Smart; Julia E Oleksak; Edward J Hartsough
Journal:  Mol Cancer Res       Date:  2020-10-01       Impact factor: 6.333

Review 10.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.